Loading...
XHEL
OPTOMED
Market cap41mUSD
Jul 09, Last price  
1.70EUR
1D
-1.16%
1Q
-26.72%
IPO
-72.58%
Name

Optomed Oyj

Chart & Performance

D1W1MN
XHEL:OPTOMED chart
P/E
P/S
2.13
EPS
Div Yield, %
Shrs. gr., 5y
8.36%
Rev. gr., 5y
5.61%
Revenues
17m
+13.67%
6,609,0006,899,00014,463,00014,977,00013,011,00014,850,00014,660,00015,100,00015,040,00017,096,000
Net income
-7m
L+21.83%
-2,758,000-2,887,000-1,268,000-2,875,000-3,177,000-4,249,000-5,472,000-4,441,000-5,450,000-6,640,000
CFO
-2m
L+55.51%
-810,000-766,000-76,000161,000-2,801,000-2,940,000-2,370,000-615,000-1,596,000-2,482,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Optomed Oyj, established in 2004 and headquartered in Oulu, Finland, is a medical technology company specializing in the development, production, and sale of portable devices for retinal examination and advanced screening software. The company operates globally, with a presence in Finland and China, structured into dedicated Devices and Software segments. Its Device division focuses on fundus cameras, serving a broad spectrum of medical specialists, including ophthalmologists, pediatricians, endocrinologists, neurologists, and general practitioners. These camera products are marketed under Optomed's own brand names such as Optomed Smartscope Pro, Aurora, Polaris, and Halo, and are also provided as OEM products under labels including Pictor Plus, Pictor Prestige, Visuscout 100, Fundus Module 300, and Signal. The Software segment offers a comprehensive suite of solutions. For eye health, this includes Avenue Eye Screen for managing the workflow of eye disease screening and monitoring (like diabetic retinopathy), Avenue Archive for healthcare data storage and transmission, Avenue Telemedicine for remote image analysis, Avenue AI for automated diabetic retinopathy screening, and Avenue Sync for seamless integration of fundus cameras with hospital systems. Beyond eye care, Optomed provides Avenue Cancer Screen for managing breast, cervical, and colorectal cancer screenings; Optomed RIS for optimizing diagnostic processes in healthcare imaging units; Sectra PACS, a scalable system for high-volume healthcare providers; Optomed Service Portal for supporting imaging service operations; Facad for visible light imaging and cephalometric tracing; and Sectra PACS Pathology, a digital solution for the distribution and diagnosis of scanned glass slides. Furthermore, Optomed extends professional IT consulting services to government bodies. The company's products and solutions are distributed through OEMs, authorized distributors, and its direct sales channels. Its primary clientele includes hospitals, specialized eye clinics, and both independent and chain optician stores.
IPO date
Dec 09, 2019
Employees
115
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT